checkAd

    DGAP-News  587  0 Kommentare MOLOGEN AG: First combination data of TLR9 agonists EnanDIM(R) with checkpoint inhibitor in preclinical tumor models - Seite 3


    MOLOGEN's pipeline focus is on new, innovative immunotherapies to treat diseases for which there is a high medical need.
    www.mologen.com


    Memberships in associations:
    Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)


    MOLOGEN(R), dSLIM(R), EnanDIM(R) and MIDGE(R) are registered trademarks of MOLOGEN AG.


    Contact

    Claudia Nickolaus
    Head of Investor Relations & Corporate Communications

    Tel: +49 - 30 - 84 17 88 - 38

    Fax: +49 - 30 - 84 17 88 - 50

    investor@mologen.com


    Note about risk for future predictions
    Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.
















    27.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de





























    Language: English
    Company: MOLOGEN AG
    Fabeckstraße 30
    14195 Berlin
    Germany
    Phone: 030 / 841788-0
    Fax: 030 / 841788-50
    E-mail: presse@mologen.com
    Internet: www.mologen.com
    ISIN: DE0006637200
    WKN: 663720
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange





     
    End of News DGAP News Service



    Lesen Sie auch



    547739  27.02.2017 




    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News MOLOGEN AG: First combination data of TLR9 agonists EnanDIM(R) with checkpoint inhibitor in preclinical tumor models - Seite 3 DGAP-News: MOLOGEN AG / Key word(s): Conference MOLOGEN AG: First combination data of TLR9 agonists EnanDIM(R) with checkpoint inhibitor in preclinical tumor models 27.02.2017 / 10:01 The issuer is solely responsible for the content of this …